This Cheap Michigan Biotech Could Have Major Phase II Catalysts Coming
3/20/2017 7:13:44 AM
Shares have traded relatively flat since the company's initial public offering.
Share price could runup into three data readouts from phase 2b trials.
Principal asset gemcabene appears to have a differentiated profile that could allow the company to carve its niche in several indications in the cardiometabolic arena.
comments powered by